SU11248 (Sunitinib) does inhibit tumor growth and angiogenesis in an ovarian cancer murine xenograft model

Bauerschlag, DO; Schem, C; Tiwari, Sunil Kumar; Meinhold‐Heerlein, Ivo; Mundhenke, Christoph; Weigel, Marion T.; Egberts, JH; Kalthoff, Holger; Jonat, W.; Maass, N.

doi:10.1200/jco.2008.26.15_suppl.16557

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The FDA granted sunitinib for the treatment of advanced kidney cancer and partial gastrointestinal stromal and neuroendocrine tumors, while its application in OC remains in clinical trials ( Leone Roberti Maggiore et al, 2013 ). In a xenograft mouse model, sunitinib therapy significantly reduced the tumor microvascular density, and also inhibited tumor growth and peritoneal metastasis ( Bauerschlag et al, 2010 ). The AGO-OVAR2.11 phase II trial showed that sunitinib exhibited feasibly and moderate activity in patients with recurrent Pt-resistant OC, and the non-continuous therapy schedule showed better superiority compared with continuous treatment ( Baumann et al, 2012 ).…”

Section: Molecular Targets and Agents Against Angiogenesismentioning

confidence: 99%

Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine

et al. 2023

View full text Add to dashboard Cite

Ovarian cancer (OC) remains the most fatal disease of gynecologic malignant tumors. Angiogenesis refers to the development of new vessels from pre-existing ones, which is responsible for supplying nutrients and removing metabolic waste. Although not yet completely understood, tumor vascularization is orchestrated by multiple secreted factors and signaling pathways. The most central proangiogenic signal, vascular endothelial growth factor (VEGF)/VEGFR signaling, is also the primary target of initial clinical anti-angiogenic effort. However, the efficiency of therapy has so far been modest due to the low response rate and rapidly emerging acquiring resistance. This review focused on the current understanding of the in-depth mechanisms of tumor angiogenesis, together with the newest reports of clinical trial outcomes and resistance mechanism of anti-angiogenic agents in OC. We also emphatically summarized and analyzed previously reported biomarkers and predictive models to describe the prospect of precision therapy of anti-angiogenic drugs in OC.

show abstract

Section: Molecular Targets and Agents Against Angiogenesismentioning

confidence: 99%

Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Sunitinib increases OSR2 mRNA expression when it interacts with HMGA1, but it decreases PSAT1 mRNA expression when it interacts with PSAT1. Sunitinib inhibits several tyrosine kinases that target VEGFR receptors and receptor protein tyrosine kinases [26]. Sunitinib has been shown to be effective in the treatment of breast and lung cancer.…”

Section: Molecular Target For Novel Treatment On Ovarian Cancermentioning

confidence: 99%

“…[27]. Sunitinib has been shown in preclinical studies to inhibit peritoneal tumor metastasis and tumor angiogenesis [26].…”

Section: Molecular Target For Novel Treatment On Ovarian Cancermentioning

confidence: 99%

From the Drugbank Application to the Novel Drugs: A Pharmacogenomic Summary

Abiyana,

Santoso,

Pribadi

et al. 2024

E3S Web Conf.

View full text Add to dashboard Cite

Computational drug research has grown in popularity in recent decades because to lower risks, time, cost, and resource needs as compared to traditional experimental approaches. The DrugBank application has expanded the number and quality of pharmacological activities and drug metabolic pathways depicted visually. The review elaborated a number of novel drugs and the molecular target mechanisms discovered with DrugBank. The study involves papers indexed by Scopus and Pub Med, the search uses a combination of the following keyword variants; “Drugbank AND Repurposing Drug”, “Drugbank AND Pharmacogenomic”. This study only used original articles in English that were published peer reviewed journals from October 2020 to November 2022. Thus, the screening results of library sources were narrowed to 9 original articles that met the inclusion criteria. Our result highlighted the involvement of 23 drug-targeting molecules in nine spesific diseases. The result shows 46 lists of repurposing drugs, four of which have the potential to be developed as prostate cancer treatments, five new drugs for ovarian cancer five new breast cancer drugs, eight new drugs highly recommended for depression, five candidates for atopic dermatitis, two recommended treatment for asthma, a novel drug for multiple sclerosis, and 18 potential medication for chronic hepatitis B.

show abstract

SU11248 (Sunitinib) does inhibit tumor growth and angiogenesis in an ovarian cancer murine xenograft model

Cited by 2 publications

References 0 publications

Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine

Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine

From the Drugbank Application to the Novel Drugs: A Pharmacogenomic Summary

Contact Info

Product

Resources

About